Melphalan and Gastrointestinal toxicity - a phase IV clinical study of FDA data

Summary:

Gastrointestinal toxicity is reported as a side effect among people who take Melphalan (melphalan), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Bortezomib, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Gastrointestinal toxicity when taking Melphalan. It is created by eHealthMe based on reports of 20,050 people who have side effects when taking Melphalan from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Gastrointestinal toxicity?

Gastrointestinal toxicity (damage to digestive tract by any substance) is found to be associated with 307 drugs and 343 conditions by eHealthMe. Check the latest studies of Gastrointestinal toxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

20,050 people reported to have side effects when taking Melphalan.
Among them, 59 people (0.29%) have Gastrointestinal toxicity.

Could Melphalan cause Gastrointestinal toxicity?

Among these 59 people:

How long have people been on Melphalan when they have Gastrointestinal toxicity? *

What is the gender of people who have Gastrointestinal toxicity when taking Melphalan? *

female: 60.61 %
male: 39.39 %

What is the age of people who have Gastrointestinal toxicity when taking Melphalan? *

What are other drugs people take besides Melphalan? *

What are other side effects people have besides Gastrointestinal toxicity? *

Thrombocytopenia (decrease of platelets in blood): 17 people, 28.81%
Mucosal Inflammation (infection of mucous membrane): 14 people, 23.73%
Febrile Neutropenia (fever with reduced white blood cells): 14 people, 23.73%
Neuropathy Peripheral (surface nerve damage): 13 people, 22.03%
Anaemia (lack of blood): 12 people, 20.34%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 18.64%
Infection: 9 people, 15.25%
Fatigue (feeling of tiredness): 8 people, 13.56%
Death: 7 people, 11.86%
Diarrhea: 7 people, 11.86%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 21 people, 35.59%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 13.56%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 3.39%
Hodgkin's Disease Refractory (cancer originating from white blood cells -refractory): 2 people, 3.39%
Immunodeficiency Disorders: 2 people, 3.39%
Malignant Lymphoid Neoplasm (malignant growth or tumour caused by abnormal and uncontrolled cell division in lymph node): 2 people, 3.39%
Ewing's Sarcoma (malignant small, round, blue cell tumour): 2 people, 3.39%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 2 people, 3.39%
Neoplasm Malignant (cancer tumour): 2 people, 3.39%
Bone Marrow Conditioning Regimen: 2 people, 3.39%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and have Gastrointestinal toxicity?

- Check whether Gastrointestinal toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan:

Melphalan (20,052 reports)

Browse all side effects of Melphalan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal toxicity:

Gastrointestinal toxicity (307 drugs)

Browse all the conditions that are associated with Gastrointestinal toxicity:

Gastrointestinal toxicity (343 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on melphalan (the active ingredients of Melphalan) and Melphalan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.